Gianluca Vita

Dr. Gianluca Vita

Nemo Sud Clinicl Center for neuromuscular disorders
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2016 in Neuromuscular Disorders
Verified
Journal Article
Open access
PBPaolo Bettica
Paolo Bettica
SPStefania Petrini
Stefania Petrini
VDValentina D'ORia
Valentina D'ORia
ADAdele D'AMico
Adele D'AMico
MCMichela Catteruccia
Michela Catteruccia
EMEugenio Mercuri
Eugenio Mercuri
Duchenne Muscular Dystrophy (DMD) is caused by mutations in the dystrophin gene leading to dystrophin deficiency, muscle fiber degeneration and progressive fibrotic replacement of muscles. Givinostat, a histone deacetylase (HDAC) inhibitor, significantly reduced fibrosis and promoted compensatory muscle regeneration in mdx mice. This study was conducted to evaluate whether the beneficial histological effects of Givinostat could be extended to DMD boys. Twenty ambulant DMD boys aged 7 to <11 years on stable corticosteroid treatment were enrolled in the study and treated for ≥12 months with Givinostat. A muscle biopsy was collected at the beginning and at the end of treatment to evaluate the amount of muscle and fibrotic tissue. Histological effects were the primary objectives of the study. Treatment with Givinostat significantly increased the fraction of muscle tissue in the biopsies and reduced the amount of fibrotic tissue. It also substantially reduced tissue necrosis and fatty replacement. Overall the drug was safe and tolerated. Improvement in functional tests was not observed in this study, but the sample size of the study was not sufficient to draw definitive conclusions. This study showed that treatment with Givinostat for more than 1 year significantly counteracted histological disease progression in ambulant DMD boys aged 7 to 10 years.

1 February 2016 in Neuromuscular Disorders
Verified
Journal Article
Open access
EMEugenio Mercuri
Eugenio Mercuri
RFRichard Finkel
Richard Finkel
JMJacqueline Montes
Jacqueline Montes
EMElena S. Mazzone
Elena S. Mazzone
MSMaria Pia Sormani
Maria Pia Sormani
DVDarryl C. De Vivo
Darryl C. De Vivo
The aim of the study was to establish 12-month changes in the Hammersmith Functional motor scale in a large cohort of SMA patients, to identify patterns of disease progression and the effect of different variables. 268 patients were included in this multicentric study. Their age ranged between 2.5 and 55.5 years at baseline, 68 were ambulant and 200 non-ambulant. The baseline scores ranged between 0 and 66 (mean 23.91, SD 20.09). The 12-month change was between -14 and +9 (mean -0.56, SD 2.72). Of the 268 patients, 206 (76.86%) had changes between -2 and +2 points. Ambulant and non-ambulant subjects had a different relationship between baseline values and age (p for age X ambulation interaction = 0.007). There was no association with age in ambulant subjects, while there was a significant heterogeneity at different age for non-ambulant patients (p < 0.001). The 12-month change (adjusted for baseline) was not associated with age in ambulant patients (p = 0.34), but it was significantly different among various age groups in non-ambulant patients. Our results suggest that there are different profiles of progression in ambulant and non-ambulant patients, and that age may play an important role in the progression of non-ambulant patients.

10 November 2011 in Skeletal Radiology
Verified
Journal Article
Closed access
PDF file
MGMichele Gaeta
Michele Gaeta
SMSonia Messina
Sonia Messina
AMAchille Mileto
Achille Mileto
GVGianluca Vita
Gianluca Vita
GAGiorgio Ascenti
Giorgio Ascenti
FMFabio Minutoli
Fabio Minutoli

1 October 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MPMarika Pane
Marika Pane
EMElena Stacy Mazzone
Elena Stacy Mazzone
SSSerena Sivo
Serena Sivo
MSMaria Pia Sormani
Maria Pia Sormani
SMSonia Messina
Sonia Messina
EMEugenio Mercuri
Eugenio Mercuri
The 6 minute walk test has been recently chosen as the primary outcome measure in international multicenter clinical trials in Duchenne muscular dystrophy ambulant patients. The aim of the study was to assess the spectrum of changes at 3 years in the individual measures, their correlation with steroid treatment, age and 6 minute walk test values at baseline. Ninety-six patients from 11 centers were assessed at baseline and 12, 24 and 36 months after baseline using the 6 minute walk test and the North Star Ambulatory Assessment. Three boys (3%) lost the ability to perform the 6 minute walk test within 12 months, another 13 between 12 and 24 months (14%) and 11 between 24 and 36 months (12%). The 6 minute walk test showed an average overall decline of −15.8 (SD 77.3) m at 12 months, of −58.9 (SD 125.7) m at 24 months and −104.22 (SD 146.2) m at 36 months. The changes were significantly different in the two baseline age groups and according to the baseline 6 minute walk test values (below and above 350 m) (p<0.001). The changes were also significantly different according to steroid treatment (p = 0.01). Similar findings were found for the North Star Ambulatory Assessment. These are the first 36 month longitudinal data using the 6 minute walk test and North Star Ambulatory Assessment in Duchenne muscular dystrophy. Our findings will help not only to have a better idea of the progression of the disorder but also provide reference data that can be used to compare with the results of the long term extension studies that are becoming available.

11 January 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EMElena Stacy Mazzone
Elena Stacy Mazzone
MPMarika Pane
Marika Pane
MSMaria Pia Sormani
Maria Pia Sormani
RSRoberta Scalise
Roberta Scalise
ABangela berardinelli
angela berardinelli
EMEugenio Mercuri
Eugenio Mercuri
The aim of the study was i) to assess the spectrum of changes over 24 months in ambulant boys affected by Duchenne muscular dystrophy, ii) to establish the difference between the first and the second year results and iii) to identify possible early markers of loss of ambulation. One hundred and thirteen patients (age range 4.1–17, mean 8.2) fulfilled the inclusion criteria, 67 of the 113 were on daily and 40 on intermittent steroids, while 6 were not on steroids. All were assessed using the 6 Minute Walk Test (6MWT), the North Star Ambulatory Assessment (NSAA) and timed test. On the 6MWT there was an average overall decline of −22.7 (SD 81.0) in the first year and of −64.7 (SD 123.1) in the second year. On the NSAA the average overall decline was of −1.86 (SD 4.21) in the first year and of −2.98 (SD 5.19) in the second year. Fourteen children lost ambulation, one in the first year and the other 13 in the second year of the study. A distance of at least 330 meters on the 6MWT, or a NSAA score of 18 at baseline reduced significantly the risk of losing ambulation within 2 years. These results can be of help at the time of using inclusion criteria for a study in ambulant patients in order to minimize the risk of patients who may lose ambulation within the time of the trial.

1 March 2014 in Neuromuscular Disorders
Verified
Journal Article
Open access
MPMarika Pane
Marika Pane
EMElena S. Mazzone
Elena S. Mazzone
LFLavinia Fanelli
Lavinia Fanelli
RSRoberto De Sanctis
Roberto De Sanctis
FBFlaviana Bianco
Flaviana Bianco
EMEugenio Mercuri
Eugenio Mercuri
The Performance of Upper Limb was specifically designed to assess upper limb function in Duchenne muscular dystrophy. The aim of this study was to assess (1) a cohort of typically developing children from the age of 3years onwards in order to identify the age when the activities assessed in the individual items are consistently achieved, and (2) a cohort of 322 Duchenne children and young adults to establish the range of findings at different ages. We collected normative data for the scale validation on 277 typically developing subjects from 3 to 25years old. A full score was consistently achieved by the age of 5years. In the Duchenne cohort there was early involvement of the proximal muscles and a proximal to distal progressive involvement. The scale was capable of measuring small distal movements, related to activities of daily living, even in the oldest and weakest patients. Our data suggest that the assessment can be reliably used in both ambulant and non ambulant Duchenne patients in a multicentric setting and could therefore be considered as an outcome measure for future trials.